Disclosed is a compound represented by the formula (I):
Wherein R
1
and R
2
independently represent a hydrogen atom, a lower alkyl group or the like; X
1
, X
2
and X
3
independently represent a methine group or a nitrogen atom; Y
1
and Y
3
independently represent a single bond, —O— or the like; Y
2
represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z
1
and Z
2
independently represent a single bond, a C
1-4
alkylene group or the like; Ar
1
represents an aromatic carbocyclic ring or the like; and Ar
2
represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.
The present invention provides an imidazopyridine compound represented by formula (I),
wherein R
1
and R
2
each independently represent a C
1-6
alkyl group et al; R
3
and R
4
each independently represent a hydrogen atom, a methyl et al; Ar
1
is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar
2
represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents —(CH
2
)
m
et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.
The present invention provides an imidazopyridine compound represented by formula (I),
wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.
Disclosed is a compound represented by the formula (I):
Wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like; X1 , X2 and X3 independently represent a methine group or a nitrogen atom; Y1 and Y3 independently represent a single bond, -O- or the like; Y2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z1 and Z2 independently represent a single bond, a C1-4 alkylene group or the like; Ar1 represents an aromatic carbocyclic ring or the like; and Ar2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.